No Data
No Data
Rapport Therapeutics(RAPP.US) Director Buys US$1.08 Million in Common Stock
$Rapport Therapeutics(RAPP.US)$ Director HEALY JAMES purchased 44,032 shares of common stock on Jul 1, 2024 at an average price of $24.518 for a total value of $1.08 million.Source: Announcement What
Stifel Starts Rapport at Buy, Cites Lead Drug Candidate RAP-219
TD Cowen Initiates Rapport Therapeutics(RAPP.US) With Buy Rating
TD Cowen analyst Joseph Thome initiates coverage on $Rapport Therapeutics(RAPP.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 34.2% and a total average return of
Rapport Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 50.09% Stifel → $35 Initiates Coverage On → Buy
Express News | Rapport Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating
Stifel Initiates Rapport Therapeutics(RAPP.US) With Buy Rating, Announces Target Price $35
Stifel analyst Paul Matteis initiates coverage on $Rapport Therapeutics(RAPP.US)$ with a buy rating, and sets the target price at $35.According to TipRanks data, the analyst has a success rate of 47.5
No Data